C
Christian Graeb
Researcher at Ludwig Maximilian University of Munich
Publications - 52
Citations - 2485
Christian Graeb is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 25, co-authored 44 publications receiving 2297 citations. Previous affiliations of Christian Graeb include University of Wisconsin-Madison & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.
TL;DR: The current literature regarding the pro- and anti-neoplastic effects of immunosuppressive agents on cancer growth and development is presented.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
Gudrun E. Koehl,Joachim Andrassy,Markus Guba,Sebastian Richter,Alexander Kroemer,Marcus N. Scherer,Markus Steinbauer,Christian Graeb,Hans J. Schlitt,Karl-Walter Jauch,Edward K Geissler +10 more
TL;DR: This study demonstrates that rapamycin simultaneously protects allografts from rejection and attacks tumors in a complex transplant-tumor situation, and in vitro experiments showed that CsA promotes angiogenesis by a transforming growth factor-β–related mechanism, and that this effect is abrogated by Rapamycin.
Journal ArticleDOI
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
Stephan Huber,Christiane J. Bruns,Gerald Schmid,Patrick C. Hermann,Claudius Conrad,Hanno Niess,Ralf Huss,Christian Graeb,K. W. Jauch,Christopher Heeschen,Markus Guba +10 more
TL;DR: In this article, the authors investigated whether the mTOR inhibitor rapamycin, besides its known antihemangiogenic effect, also impedes regenerative lymphangiogenesis, and provided extensive experimental evidence for an antilymphangiogenicity of mTOR inhibition suggesting that the early use of m TOR inhibitor following tissue injury should be avoided.
Journal ArticleDOI
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the transplantation center munich
C. Wimmer,Markus Rentsch,Alexander Crispin,W. D. Illner,Helmut Arbogast,Christian Graeb,K. W. Jauch,Markus Guba +7 more
TL;DR: Interestingly, the use of IL-2-receptor antagonists significantly reduced the tumor risk of transplant recipients and mammalian target of rapamycin (mTOR) inhibitor-based immunosuppressive protocols showed a clear tendency for lower malignancy rates.